Evidence map›Paper›PMID 35530933›Full record

ArticleAnnals of translational medicine2022

Long-term outcomes and prognosis for patients with sarcomatoid hepatocellular carcinoma.

Cheng Zhou, Xin Zhang, Kaiqian Zhou, Yingyong Hou, Feiyu Chen, Xiangyu Zhang, Yuan Ji, Shuangjian Qiu, Jia Fan, Jian Zhou and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Cheng Zhou *Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xin Zhang *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Kaiqian Zhou *Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Feiyu ChenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiangyu ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan JiDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shuangjian QiuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jia FanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jian ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuhong ZhouDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng WangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNZhongshan Hospital · CNState Key Laboratory of Genetic EngineeringSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Characterized by spindle cell composition in hepatocellular carcinoma tumor, sarcomatoid hepatocellular carcinoma (SHC) is a rare malignant with poor prognosis. In this study, we aimed to evaluate the clinical and pathological features of SHC and establish a nomogram that can predict long-term outcomes of the disease. Methods: We retrospectively analyzed 63 patients who were diagnosed with SHC between October 2007 and November 2016 and used immunohistochemistry (IHC) to assessed various markers in liver samples. The clinical data and the histological and pathological findings were collected and used to build a nomogram to predict survival. Results: The median overall survival (OS) and the recurrence-free survival (RFS) in SHC were 23.2 and 8.4 months, respectively. High expression levels of tyrosine-protein kinase Met (17/63, 27.0%) were associated with poorer RFS (P=0.040). A panel of markers, consisting heat-shock protein 70 (HSP70), glutamine synthetase (GS), and glypican-3 (GPC3), merged as an independent risk factor for treatment outcomes. The nomogram, which including this panel of markers, predicted OS times with a concordance-index (C-index) score of 0.758 (95% CI: 0.672-0.843) in the training set and 0.832 (95% CI: 0.712-0.952) in the validation set. The use of the nomogram showed marked improvements in the prediction of patient outcomes compared with conventional staging systems (P<0.05). Conclusions: Diagnosis of SHC is rare and has a relatively poor prognosis. A panel of markers HSP70, GS and GPC3 served as an independent prognostic factor for SHC.

Indexed as

glutamine synthetase (GS)glypican-3 (GPC3)heat-shock protein 70 (HSP70)nomogramSarcomatoid hepatocellular carcinoma (SHC)

Identifiers

PMID35530933
PMCPMC9073769
OpenAlexW4207039093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.